The interplay between cell signalling and the mevalonate pathway in cancer
Cet article passe en revue les travaux récents suggérant l'intérêt de cibler des enzymes de la voie de signalisation du mévalonate, notamment à l'aide de médicaments de la famille des statines, pour développer des traitements anticancéreux
The mevalonate (MVA) pathway is an essential metabolic pathway that uses acetyl-CoA to produce sterols and isoprenoids that are integral to tumour growth and progression. In recent years, many oncogenic signalling pathways have been shown to increase the activity and/or the expression of MVA pathway enzymes. This Review summarizes recent advances and discusses unique opportunities for immediately targeting this metabolic vulnerability in cancer with agents that have been approved for other therapeutic uses, such as the statin family of drugs, to improve outcomes for cancer patients.